Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
- Publication of a peer-reviewed study favorably comparing TRUFORMA platform for feline hyperthyroidism diagnosis to CLIA platforms
- TRUFORMA's BAW technology offers more accurate results, improving early detection of hyperthyroidism
- Collaboration with researchers like Dr. Mark E. Peterson to validate TRUFORMA's effectiveness
- Ongoing clinical studies and commitment to advancing veterinary care
- TRUFORMA provides rapid, reliable diagnostic results with reference lab quality for various animal conditions
- None.
Insights
The recent study highlighting the superiority of Zomedica's TRUFORMA Bulk Acoustic Wave (BAW) diagnostic platform in diagnosing feline hyperthyroidism represents a significant advancement in veterinary diagnostics. The ability to more accurately identify hyperthyroid cats is crucial since this condition is common in older cats and can significantly impact their health. The study's findings suggest that the TRUFORMA BAW platform could reduce the rate of misdiagnosis associated with the traditional TSH-CLIA assays, which is a substantial improvement in diagnostic accuracy.
From a veterinary health perspective, the immediate benefit is the potential for improved patient outcomes due to earlier and more accurate diagnoses. This is particularly important for conditions like hyperthyroidism, where timely intervention can greatly enhance the quality of life for affected animals. The in-clinic convenience of obtaining results in under thirty minutes with TRUFORMA also means that veterinarians can make faster clinical decisions, enhancing the overall efficiency of veterinary practices.
The publication of this peer-reviewed study is likely to bolster Zomedica's market position within the veterinary diagnostic sector. The validation of the TRUFORMA platform's effectiveness in diagnosing feline hyperthyroidism could lead to increased adoption by veterinary clinics seeking to offer the most accurate and efficient care. The impact on Zomedica's business could be multifaceted, potentially increasing sales of the TRUFORMA diagnostic platform and associated testing reagents.
In the broader context of the veterinary diagnostics market, which is experiencing growth driven by pet owners' increasing willingness to spend on pet healthcare, Zomedica's innovation may capture a significant market share. This could also attract investor interest as the company demonstrates its commitment to advancing veterinary diagnostics through technological innovation and research collaborations.
The financial implications for Zomedica stemming from this study are potentially substantial. As the company did not fund the research, the positive results lend credibility without the associated research and development expenses. This third-party validation could lead to an uptick in investor confidence, potentially impacting Zomedica's stock performance positively. The study's findings may also pave the way for future product developments and assay additions to the TRUFORMA platform, which could further drive revenue growth.
It is essential to monitor how this news translates into actual sales and market penetration. While the study's results are promising, the real test will be the veterinary community's adoption rate and the subsequent financial performance of the TRUFORMA product line. Investors should watch for follow-up reports on sales figures and market feedback to gauge the long-term financial impact of this development on Zomedica's business.
ANN ARBOR, MI / ACCESSWIRE / March 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a peer-reviewed research study favorably comparing the capabilities for the diagnosis of feline hyperthyroidism of its novel, point-of-care TRUFORMA Bulk Acoustic Wave (BAW) diagnostic platform to chemiluminescent immunoassay (CLIA) platforms currently broadly utilized by reference laboratories globally.
The authors conclude that, "this new TSH-BAW assay more accurately identifies hyperthyroid cats than the current TSH-CLIA assay and would improve the early diagnosis of hyperthyroidism." The article, titled "Evaluation of a novel, sensitive thyroid-stimulating hormone assay as a diagnostic test for thyroid disease in cats" was published in American Journal of Veterinary Research and is available here: https://pubmed.ncbi.nlm.nih.gov/38382201/. Zomedica Inc, provided technical assistance and sample testing reagents, however, Zomedica did not provide financial support or funding for this research and did not have any influence on the results.
"Research suggests that approximately
"The extended dynamic range of the TRUFORMA TSH assay allows the quantification of high and low concentrations of TSH which is vital for accurate diagnosis of canine and particularly feline thyroid disease," said Ashley Wood, PhD, Zomedica's Vice President of Research & Development. "This paper confirms and documents the value of TRUFORMA's BAW feline-optimized assay over the reference lab TSH assay as well as well as over other frequently utilized assays. As TRUFORMA is also fully utilized in the clinic, veterinarians and their patients will also have the added benefit of results in less than half an hour rather than waiting for results from an outside reference lab."
The TRUFORMA diagnostic platform utilizes unique BAW technology that provides highly precise and sensitive measurements at levels that other diagnostic methods utilizing optical-based technologies cannot provide. Currently, TRUFORMA in-clinic diagnostic systems provide accurate, rapid, and reliable diagnostic results to veterinarians to assist in their diagnosis and treatment of complex thyroid and adrenal conditions, canine non-infectious gastrointestinal disease and the first point-of-care assay for equine Cushing's disease, all providing reference lab quality with point of care convenience.
"We are grateful to have the support of Dr. Peterson and his colleagues in validating the TRUFORMA platform as the state of the art for in-clinic diagnosis of feline hyperthyroidism," commented Larry Heaton, Zomedica's Chief Executive Officer. "Zomedica places a top priority in collaborating with veterinary researchers to advance animal healthcare. We remain dedicated to accelerating development of additional highly beneficial assays through our recent acquisition and integration of TRUFORMA's platform developer, and it's rewarding to know that our efforts are yielding such exciting results for the veterinary community."
Zomedica remains steadfast in its commitment to staying at the forefront of diagnostic options in veterinary care. It's unwavering dedication to advancing veterinary care is demonstrated through its ongoing clinical studies, which continue to advance veterinary science.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://m.facebook.com/zomedica
- X (formerly Twitter): https://twitter.com/zomedica
- Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What does Zomedica announce in the press release?
How does the study suggest TRUFORMA's BAW technology benefits the diagnosis of hyperthyroidism?
Who is Dr. Mark E. Peterson and what is his role in the study?
What is Zomedica's commitment to enhancing animal healthcare?
What quality of diagnostic results does TRUFORMA provide?
